Linaprazan glurate inhibits exogenously or endogenously stimulated gastric acid secretion. Linaprazan glurate exhibits several advantageous properties, such as fast onset, high in vivo potency and/or long duration of action. Linaprazan glurate is useful in the research of gastrointestinal inflammatory diseases and peptic ulcer diseases (extracted from patent WO2010063876A1)[1].

[1]. Mikael DahlstrÖm, et al. Imidazopyridine derivatives which inhibit the secretion of gastric acid. Patent WO2010063876A1.